Table 3.
Visual Outcomes After Intraocular Inflammation Adverse Events
| Intraocular inflammation AE (MedDRA preferred term) | Treatment arm | Worst change from baseline BCVA after AE (letters) | BCVA change from baseline at escape to SoC or study exit (letters) |
|---|---|---|---|
| Iritis | Abicipar 1 mg | −5 | −1 |
| Uveitis | Abicipar 1 mg | −2 | +4 |
| Vitritis | Abicipar 1 mg | +14 | +22 |
| Iritis | Abicipar 2 mg | NA | +2 |
| Choroiditis | Abicipar 2 mg | −19 | +7 |
AE, adverse event; BCVA, best-corrected visual acuity; MedDRA, medical dictionary for regulatory activities; NA, not available; SoC, standard of care.